GLP-2 - 30 mg

Synthetic dual agonist of the GIP and GLP-1 receptors (research designation LY3298176). Studied for combined GIP and GLP-1 receptor activation across glucose-metabolism and energy-balance pathways. Research focus: Glycemic Regulation, Satiety Signaling, Body Composition, Dual-Incretin Pharmacology. Documented research areas: Glycemic regulation, Satiety signaling, Energy balance. Research Use Only — not for human or veterinary consumption. Supplied as a reference material for in-vitro and in-vivo laboratory research; not evaluated by the FDA and not intended to diagnose, treat, cure, or prevent any disease.